Pancreatic Cancer Research

ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Ce Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1465-4905; OpenAlex author ID A5101599428. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper

Papers 11

  1. Corrigendum to "LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway" [Cancer Lett.374 (2016) 261-27… Co-author DOI 10.1016/j.canlet.2024.217239↗
  2. TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, preventive, and personalized medicine. Co-author DOI 10.1007/s13167-022-00287-0↗
  3. microRNA-569 inhibits tumor metastasis in pancreatic cancer by directly targeting NUSAP1. Last author DOI 10.18632/aging.204035↗
  4. Epithelial cell transforming 2 is regulated by Yes-associated protein 1 and mediates pancreatic cancer progression and metastasis. Co-author DOI 10.1152/ajpgi.00185.2020↗
  5. PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells. Co-author DOI 10.1007/s12032-020-01372-y↗
  6. DNMT3a promotes proliferation by activating the STAT3 signaling pathway and depressing apoptosis in pancreatic cancer. Co-author DOI 10.2147/cmar.s201610↗
  7. MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3389/fphys.2019.00147↗
  8. MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-018-4526-z↗
  9. Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.18714↗
  10. LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway. Co-author DOI 10.1016/j.canlet.2016.02.018↗
  11. MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells. First author DOI 10.18632/oncotarget.11001↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaofang Che · 6 shared papers, 2016–2022 · strength 0.59
  2. Xiujuan Qu · 4 shared papers, 2016–2022 · strength 0.38
  3. Hanxiang Zhan · 2 shared papers, 2016–2024 · strength 0.27
  4. Jianwei Xu · 2 shared papers, 2016–2024 · strength 0.27
  5. Qiang Wang · 2 shared papers, 2019–2021 · strength 0.21
  6. Nicholas N. Nissen · 2 shared papers, 2019–2021 · strength 0.21
  7. Stephen Jacob Pandol · 2 shared papers, 2019–2021 · strength 0.21
  8. Na Song · 2 shared papers, 2019–2020 · strength 0.21
  9. Wei Jing · 2 shared papers, 2019–2020 · strength 0.21
  10. San-yuan Hu · 1 shared paper, 2024 · strength 0.21
  11. Xiaohui Guo · 1 shared paper, 2022 · strength 0.19
  12. Qiaoyun Chu · 1 shared paper, 2022 · strength 0.19
  13. Simeng Zhang · 1 shared paper, 2022 · strength 0.19
  14. Guan Wang · 1 shared paper, 2022 · strength 0.19
  15. Yunpeng Liu · 2 shared papers, 2018–2020 · strength 0.18
  16. Xianghong Yang · 2 shared papers, 2016–2018 · strength 0.12
  17. Qian Dong · 2 shared papers, 2016–2017 · strength 0.12
  18. Xiang-Hong Yang · 1 shared paper, 2019 · strength 0.10
  19. Susan Morvaridi · 1 shared paper, 2019 · strength 0.09
  20. Mouad Edderkaoui · 1 shared paper, 2019 · strength 0.09
  21. Zhi Li · 1 shared paper, 2017 · strength 0.06
  22. Sanyuan Hu · 1 shared paper, 2016 · strength 0.06
  23. Lei Wang · 1 shared paper, 2016 · strength 0.06
  24. Bin Zhou · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.